Billerica, MA – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, announced a $70 million investment to expand its state-of-the-art research and development (R&D) facility in Billerica.
The new building will span 145,000sf, offering new laboratory and collaborative working space to accommodate approximately 400 new and current R&D employees focused on advancing science in oncology, immuno-oncology, and immunology.
When construction is completed in 2021, the building will offer wet labs, office space, and a cafeteria for the campus. Consistent with previous projects, the building will be constructed to the highest environmental and employee wellness standards by seeking LEED and WELL certifications.
With this latest project, Merck will have invested more than $150 million in infrastructure to advance biopharmaceutical R&D in the state of Massachusetts in recent years, with more than 150 new jobs added to its growing U.S. R&D hub in Billerica since 2011.
Merck KGaA, Darmstadt, Germany’s U.S. presence is comprised of three businesses — healthcare, life science and performance materials — with nearly 10,000 employees working in R&D, manufacturing, and corporate roles in almost 60 sites countrywide.
Within the state of Massachusetts, more than 2,800 professionals work across 10 locations.